SG Americas Securities LLC Sells 28,515 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

SG Americas Securities LLC reduced its position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 90.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,939 shares of the company's stock after selling 28,515 shares during the quarter. SG Americas Securities LLC's holdings in Revolution Medicines were worth $129,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in RVMD. GAMMA Investing LLC grew its stake in shares of Revolution Medicines by 55.8% in the third quarter. GAMMA Investing LLC now owns 620 shares of the company's stock valued at $28,000 after acquiring an additional 222 shares in the last quarter. Quarry LP acquired a new position in shares of Revolution Medicines in the third quarter valued at about $82,000. Values First Advisors Inc. acquired a new position in shares of Revolution Medicines in the third quarter valued at about $93,000. KBC Group NV grew its stake in shares of Revolution Medicines by 12.9% in the third quarter. KBC Group NV now owns 3,221 shares of the company's stock valued at $146,000 after acquiring an additional 368 shares in the last quarter. Finally, Avanza Fonder AB acquired a new position in shares of Revolution Medicines in the fourth quarter valued at about $173,000. 94.34% of the stock is owned by institutional investors.

Analyst Ratings Changes

RVMD has been the topic of a number of analyst reports. Piper Sandler increased their price objective on shares of Revolution Medicines from $57.00 to $70.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Wedbush reiterated an "outperform" rating and set a $70.00 price objective on shares of Revolution Medicines in a research note on Monday, December 2nd. Needham & Company LLC reiterated a "buy" rating and set a $68.00 price objective on shares of Revolution Medicines in a research note on Tuesday, December 3rd. HC Wainwright increased their price objective on shares of Revolution Medicines from $64.00 to $72.00 and gave the stock a "buy" rating in a research note on Wednesday, December 4th. Finally, Guggenheim increased their price objective on shares of Revolution Medicines from $82.00 to $87.00 and gave the stock a "buy" rating in a research note on Tuesday, December 3rd. Eleven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $66.25.

Insider Activity at Revolution Medicines

In related news, CFO Jack Anders sold 2,635 shares of the firm's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $45.40, for a total value of $119,629.00. Following the completion of the transaction, the chief financial officer now owns 96,470 shares in the company, valued at $4,379,738. This trade represents a 2.66 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Margaret A. Horn sold 4,329 shares of the business's stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $45.40, for a total transaction of $196,536.60. Following the completion of the transaction, the chief operating officer now owns 127,991 shares in the company, valued at $5,810,791.40. This trade represents a 3.27 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 18,678 shares of company stock worth $847,981 in the last quarter. 8.00% of the stock is owned by insiders.

Revolution Medicines Price Performance

NASDAQ RVMD traded down $0.65 during trading hours on Friday, reaching $40.67. The company's stock had a trading volume of 1,461,401 shares, compared to its average volume of 1,412,222. The firm has a fifty day simple moving average of $42.95 and a 200-day simple moving average of $46.35. The stock has a market cap of $6.84 billion, a P/E ratio of -11.33 and a beta of 1.45. Revolution Medicines, Inc. has a 52 week low of $28.43 and a 52 week high of $62.40.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.